We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Opportunities and Challenges of Disease Progression Modeling in Drug Development – An IQ Perspective.
- Authors
Goteti, Kosalaram; Hanan, Nathan; Magee, Mindy; Wojciechowski, Jessica; Mensing, Sven; Lalovic, Bojan; Hang, Yaming; Solms, Alexander; Singh, Indrajeet; Singh, Rajendra; Rieger, Theodore Robert; Jin, Jin Y.
- Abstract
Disease progression modeling (DPM) represents an important model‐informed drug development framework. The scientific communities support the use of DPM to accelerate and increase efficiency in drug development. This article summarizes International Consortium for Innovation & Quality (IQ) in Pharmaceutical Development mediated survey conducted across multiple biopharmaceutical companies on challenges and opportunities for DPM. Additionally, this summary highlights the viewpoints of IQ from the 2021 workshop hosted by the US Food and Drug Administration (FDA). Sixteen pharmaceutical companies participated in the IQ survey with 36 main questions. The types of questions included single/multiple choice, dichotomous, rank questions, and open‐ended or free text. The key results show that DPM has different representation, it encompasses natural disease history, placebo response, standard of care as background therapy, and can even be interpreted as pharmacokinetic/pharmacodynamic modeling. The most common reasons for not implementing DPM as frequently seem to be difficulties in internal cross‐functional alignment, lack of knowledge of disease/data, and time constraints. If successfully implemented, DPM can have an impact on dose selection, reduction of sample size, trial read‐out support, patient selection/stratification, and supportive evidence for regulatory interactions. The key success factors and key challenges of disease progression models were highlighted in the survey and about 24 case studies across different therapeutic areas were submitted from various survey sponsors. Although DPM is still evolving, its current impact is limited but promising. The success of such models in the future will depend on collaboration, advanced analytics, availability of and access to relevant and adequate‐quality data, collaborative regulatory guidance, and published examples of impact.
- Subjects
UNITED States. Food &; Drug Administration; DRUG development; DISEASE progression; INTELLIGENCE levels; SCIENTIFIC community; PATIENT selection
- Publication
Clinical Pharmacology & Therapeutics, 2023, Vol 114, Issue 2, p266
- ISSN
0009-9236
- Publication type
Article
- DOI
10.1002/cpt.2873